Corbus Pharmaceuticals Announces First Patient Dosed in TEMPO-1 Registrational Study of CRB-701 in Patients with 2L+ Oropharyngeal Cancer

Incidence and prevalence of OPSCC continue to rise in the U.S. largely driven by HPV infectionOPSCC is estimated to represent 1 in 2 head and neck cancer patients in the 2L+ setting in the U.S. with approximately 14,000 patients eligible for treatment annuallyNORWOOD, Mass., Sept. 29, 2026 (GLOBE N…